Skip to content

Search

WANTED: 'Flu Busters

Hundreds of healthy volunteers are needed in Perth to test the effectiveness of a current 'flu vaccine.

Bird flu vaccine produces promising results

An Australian-developed vaccine that's been trialed in Perth has been found to produce a strong immune response against the H5N1 bird flu virus.

Beating the flu bug

Perth children are being asked to volunteer for an important national study to test the effectiveness of an influenza vaccine in children.

Meningitis study aims for fewer needles

Perth researchers are investigating a new combined vaccine to protect against three causes of potentially deadly bacterial meningitis.

The Kids Research Institute Australia researcher wins Premier’s Science Award

Infectious diseases researcher, Dr Asha Bowen, has won the Early Career Scientist of the Year Premier's Science Award for 2017.

Perth researchers lead world-first clinical trial in Chile to stop COVID-19 outbreaks

Perth researchers are leading an international clinical trial focused on preventing the spread of COVID-19 by testing the effectiveness of the drug interferon in reducing the infectiousness of people who contract the virus.

The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocol

Coronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended. 

Childhood influenza vaccination rates improves with better access

More children across Australia are being vaccinated against the flu since funding was expanded and access widened under the National Immunisation Program

The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.

Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules

In Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations.